跳至主要内容
临床试验/CTRI/2020/08/027222
CTRI/2020/08/027222尚未招募2 期

Assessment of the role of Unani formulations in prevention of COVID-19 infection in high-risk population.

Hamdard Laboratories India Medicine Division0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Subjects who have got direct or indirect exposure to RT-PCR positive COVID-19 patient(s) in last 7 days and whose test is negative for COVID-19.
  • The following high risk subjects will be included in the study;
  • a.Touched body fluids of the patient.
  • b.Had direct physical contact with the body of the patient including physical examination without PPE.
  • c.Touched or cleaned the linens, clothes, or dishes of the patient.
  • d.Lives in the same household as the patient.
  • e.Anyone in close proximity (within 1 meter) of the confirmed case without precautions.
  • f.Passenger in close proximity of a symptomatic patients in a conveyance.
  • 2.Subjects without any co-morbidities of either sex aged 18-65.
  • 3. Agrees not to self-medicate or not to take the prescribed medication with chloroquine, hydroxychloroquine or other potential antivirals/other drug.
  • 4. Willingness to give informed consent.

排除标准

  • 1.COVID-19 positive patients.
  • 2.Atopic patients or persons with known allergy to herbal products
  • 3.Critically ill patients.
  • 4.Previously diagnosed with COVID-19
  • 5.Subjects on other prophylactic medications.
  • 6.Immune compromised patients
  • 7.Pregnant and lactating women.
  • 8.Patients bellow 18 and above 65 years
  • 9.Patient taking any other herbal medicine or immune-modulatory drugs
  • 10.Out station patients.

研究者

发起方
Hamdard Laboratories India Medicine Division

相似试验